Filing Flows › Procept BioRobotics (PRCT) › Q2 2026
Procept BioRobotics (PRCT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Procept BioRobotics (PRCT) reported revenue of $94.5M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +14% from the quarter before. Operating margin was -29.0%, net loss $26.9M (28.4% of revenue).
Procept BioRobotics, Q2 2026: revenue $94.5M (+19% year over year), operating margin -29.0%, net loss $26.9M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $94.5M | +14% | +19% |
| Operating profit | −$27.4M | — | — |
| Net earnings | −$26.9M | — | — |
| Operating cash flow | −$19.3M | — | — |
What changed
Revenue was $94.5M in Q2 2026, up 19% year over year and up 14% from the previous quarter.
Gross margin was 66.0%, up 0.7 points from Q2 2025. Operating costs exceeded revenue by $27.4M, an operating margin of -29.0%. Operating expenses grew 21% against revenue growth of 19%. The fastest-growing cost line was SG&A (+24%). The quarter ended with a net loss of $26.9M, narrower than the previous quarter's $31.6M loss.
Operating cash flow was −$19.3M. Non-cash charges added back $2.0M of depreciation and amortization and $14.5M of share-based compensation. Working capital and other items used $8.9M. Capital expenditures of $3.0M exceeded it, leaving free cash flow of −$22.2M.
Questions
What was Procept BioRobotics' revenue in the second quarter 2026?
Procept BioRobotics (PRCT) reported revenue of $94.5M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +14% from the quarter before.
Was Procept BioRobotics profitable in the second quarter 2026?
Operating loss was $27.4M (-29.0% of revenue) and net loss $26.9M.